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Over the past three decades, genetic manipulations in mice have been used in
neuroscience as a major approach to investigate the in vivo function of genes and
their alterations. In particular, gene targeting techniques using embryonic stem cells
have revolutionized the field of mammalian genetics and have been at the forefront in
the generation of numerous mouse models of human brain disorders. In this review,
we will first examine childhood developmental disorders such as autism, intellectual
disability, Fragile X syndrome, and Williams-Beuren syndrome. We will then explore
psychiatric disorders such as schizophrenia and lastly, neurodegenerative disorders
including Alzheimer’s disease and Parkinson’s disease. We will outline the creation of
these mouse models that range from single gene deletions, subtle point mutations
to multi-gene manipulations, and discuss the key behavioral phenotypes of these
mice. Ultimately, the analysis of the models outlined in this review will enhance our
understanding of the in vivo role and underlying mechanisms of disease-related genes in
both normal brain function and brain disorders, and provide potential therapeutic targets
and strategies to prevent and treat these diseases.
Keywords: genetic models, transgenic mice, gene targeting, knockout, knock-in, inducible, brain disorders,
behavior
The advent of genomic manipulation in mice began in the early 1980s through the microinjection
of exogenous DNA into the pronuclei of fertilized eggs that randomly integrate into the mouse
genome. These embryos were surgically transferred into pseudopregnant recipient females,
resulting in the birth of transgenic mice harboring Mendelian inheritable traits. In particular,
this invaluable technique has allowed for the stable integration of genetic information into the
mouse genome. Therefore, over the last 30 years, the use of transgenic mice has dramatically
increased our understanding of certain disease-related genes and the consequences of ablating
specific cell types or introducing genetic mutations associated with particular human diseases.
Recent advances have also employed inducible and cell-type restricted expression systems, thus
enhancing the utility of transgenic mice. However, transgenic models have certain limitations. In
particular, the copy number and site of integration of the transgene in the mouse genome is random
and therefore, cannot be controlled, often resulting in non-specific spatial and temporal expression
of the transgene. To address these limitations, a gene targeting approach was created in the late
1980s that utilizes pluripotent embryonic stem (ES) cells, which allows for specific and targeted
changes of the endogenous genome. This technique combined with site-directed mutagenesis and
the bacteriophage Cre/loxP system has allowed for diverse, controlled, and precise manipulations
of genes of interest. In this approach, a targeting vector with desired deletions/mutations is
introduced into ES cells and undergoes homologous recombination with the endogenous wild-type
allele, resulting in deletion (knockout) or replacement (knock-in) of the wild-type copy of the
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gene. The correctly targeted ES cells are selected and then injected
to a recipient pseudopregnant foster female to generate chimeras.
These chimeras are then tested for germline transmission and
homozygosity for the targeted changes. Although, both forward
and reverse genetic mouse models have contributed to significant
advancements in biological research and a broad range of clinical
applications (Schughart et al., 2013), we will focus this review
on transgenic and gene targeting techniques that have been
employed in the generation of animal models of human brain
disorders, with particular focus on autism, intellectual disability
(ID), Fragile X syndrome (FXS), Williams- Beuren syndrome,
schizophrenia, Alzheimer’s disease (AD), and Parkinson’s disease
(PD). Specifically, we will discuss the methods and approaches
used to create the mouse models, the major phenotypes of these
models, and implications of these findings. For each disorder,
we will focus on several well-studied disease models and their
behavioral outcomes, to illustrate the power of genetic alterations
in mice as a model system to understand the diseases. However,
this review will not discuss animal models of brain diseases based
on other approaches such as those using environmental and/or
pharmacological perturbations. Ultimately, the models discussed
will enhance our understanding of the underlying mechanisms in
disease pathogenesis, and offer insights that can translate animal
studies to a clinical setting.
AUTISM SPECTRUM DISORDERS
Autism spectrum disorders (ASDs) are amongst the most
prevalent childhood disorders, affecting 1 in every 68 children
within North America (Bolivar, 2014). ASD is a developmental
disability that includes a broad spectrum of neurodevelopmental
diseases including autism, Asperger’s disorder, Rett syndrome,
childhood disintegrative disorder, and pervasive developmental
disorder. Amongst these, autism remains the most common ASD.
As characterized by DSM-V, children diagnosed with autism have
severe social interaction impairments, accompanied by concrete
social communication deficits, and stereotyped or repetitive
behaviors. Therefore, as one of the leading socioeconomic
healthcare problems, there has been ongoing effort to identify
genetic biomarkers and to elucidate their mechanisms to treat the
triad of impairments associated with this neurodevelopmental
disorder. Through genetic screening and post-mortem studies,
various candidate genes have been identified to be associated
with autism. This section will primarily focus on four well-
studied mouse models relevant to autism and the behavioral
outcomes relevant to this complex disorder. These models
are prime examples of how targeting autism-related genes
in mice can be a useful tool to investigate the cellular and
molecular processes underlying the behavioral consequences of
this complex disorder.
Neurexins
The neurexin family (NRXN1–3) of presynaptic plasma
membrane proteins are trans-synaptic cell adhesion molecules
that connect functionally pre- and post-synaptic neurons at
synapses (Sudhof, 2008; Rabaneda et al., 2014). The extracellular
domain of NRXNs interacts with post-synaptic neuroligins
(NLGN1–4) across the synaptic cleft and have an essential role
in synaptic regulation (Sudhof, 2008; Rabaneda et al., 2014).
Each NRXN gene in mammals is composed of differentially
distributed long α- and short β-NRXN isoforms. Together,
NRXNs and NLGNs are required for proper synapse maturation
and trans-synaptic neurotransmission (Varoqueaux et al., 2006;
Sudhof, 2008). Current gene association studies reveal that
hypofunction of NRXN isoforms, specifically rare single gene
variations in NRXN1, are linked to autism. Since, 0.5% of all
ASD cases appear to harbor NXRXN-1α gene deletions, Etherton
et al. (2009) generated NRXN1α knockout (KO) to uncover the
behavioral and functional consequences of this gene deletion.
NRXN1α KO mice were generated by deleting the promoter
and large first exon of the murine α-NRXN genes (Tabuchi
and Sudhof, 2002; Missler et al., 2003). These KO mice were
found to have impaired excitatory synaptic strength, decreased
prepulse inhibition, increased grooming behavior, and enhanced
motor learning (Etherton et al., 2009). The authors proposed
that NRXN1α is responsible for regulating a proper excitatory
to inhibitory balance in synaptic transmission and various
behavioral phenotypes related to autism. In addition, recent
studies demonstrate that the heterozygous deletion of NRXN1α
also resulted in impaired social memory salient with behaviors
relevant to autism (Dachtler et al., 2015). In another study,
Rabaneda et al. (2014) generated a deletion mutant to target the
NRXN1β isoform that lacks the cytoplasmic tail to uncouple
NRXN1β trans-synaptic function. Transgenic hemagglutinin
(HA)- tagged βNRXN1 1C were expressed in an inducible
manner under the control of a tetracycline-responsive promoter
element (TRE). The TRE-HA βNRXN1 1C mice were crossed
with a CaMKIIα-tTA promoter to restrict the expression of
the mutant protein in mature glutamatergic neurons in the
forebrain. As expected, the double transgenic CaMKIIα-tTA
TRE-HA βNRXN1 1C mice expressed the mutant protein
in forebrain neurons of the cortex and striatum (Rabaneda
et al., 2014). These mice displayed increased self-grooming
and deficits in social interactions, consistent with the triad of
autism-related symptoms (Rabaneda et al., 2014). However,
with the administration of the tetracycline analog, doxycycline
(DOX), in the drinking water, the expression of HA- βNRXN1
1C was suppressed. The autistic-like phenotypes were reversed
following DOX administration thereby suggesting that NRXNs
regulate functional and behavioral activity in mature neurons.
These results suggest that the presynaptic NRXN1 may cause
autistic phenotypes via interacting with its post-synaptic partner
NLGNs, altering excitatory synaptic function.
Contactin-Associated Protein 2
Contactin-associated protein 2 (CNTNAP2), a member of
the NRXN super family, encodes a neuronal transmembrane
protein (CASPR2) involved in the formation of tight axonal
connections critical for the establishment and maintenance of
neuronal circuits (Rodenas-Cuadrado et al., 2014; Gdalyahu et al.,
2015). CASPR2 is localized in juxtaparanodes of myelinated
axons and mediates interactions between neurons and glia
during development (Poliak et al., 1999). In vitro studies have
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shown that RNAi-mediated knock-down of CASPR2 impairs
the development and maturation of dendritic spines resulting
in decreased synaptic transmission (Anderson et al., 2012).
Moreover, the loss of function of CASPR2 led to impaired
synaptic connectivity and neural network assembly. Alterations
in the CNTNAP2 gene are strongly linked to language deficits
in complex neurological disorders including autism, specifically
in patients with a single nucleotide polymorphism in intron
2 of the CNTNAP2 gene (rs7794735; Arking et al., 2008).
In mice, ablation of CNTNAP2 resulted in fewer GABAergic
interneurons, neuronal migration abnormalities, and reduced
cortical neuronal synchrony (Penagarikano et al., 2011). In
addition, it was found that the intermodal localization of Kv1
channels at the juxtaparanodal region depends on the presence of
CNTNAP2 (Gordon et al., 2014). Behaviorally, CASPR2 KO mice
exhibited core autism-like symptoms including lower levels of
sociability and decreased ultrasonic vocalizations with increased
levels of grooming, hyperactivity, and deficits in reversibility
on the Morris water maze test. In a recent study, CNTNAP2
KO mice were found to have reduced spine density due to
increased spine elimination and impaired stabilization of new
spines (Gdalyahu et al., 2015). Therefore, these results together
suggest the importance of CNTNAP2 in neuronal migration
and formation of cortical neural networks that may underlie
the behavioral responses. In particular, the decreased GABAergic
interneuron activity may imply that neural asynchrony or an
excitatory and inhibitory imbalance may be a pathophysiological
mechanism to explain how information processing is impaired in
autism.
Neuroligins
Neuroligins (NLGN1–3, 4X, 4Y) are a family of post-synaptic
cell adhesion molecules that are ligands of their trans-synaptic
partner NRXN (Ichtchenko et al., 1995; Autism Genome Project
et al., 2007; Kim et al., 2008). Human genetic association studies
have linked changes in the NLGN genes with autism (Sudhof,
2008; Glessner et al., 2009). Therefore, mouse models that target
each of the different NLGN isoforms have been generated to
better understand the in vivo function of these genes and how
their mutations contribute to autism-like behaviors. KO mice
lacking individual NLGNs were created through the deletion of
exon sequences spanning the translational start site and 380 bp
of the 5′ coding sequence of the respective genes via homologous
recombination in ES cells (Varoqueaux et al., 2006). The deletion
of the NLGN1 gene, whose expression is localized at excitatory
synapses, resulted in decreased NRXN1 levels, reduced excitatory
transmission, and selective deficits in social memory, spatial
learning and memory tests, and increases in grooming (Blundell
et al., 2010). However, these authors did find a 30% increase in
the expression of NLGN3, suggesting a functional compensation
between members of the NLGN family (Blundell et al., 2010).
Moreover, these KO mice exhibited deficits in hippocampal
long term potential (LTP), the most extensively studied form of
long-lasting synaptic plasticity widely regarded as the cellular
mechanism for learning and memory, which was accompanied
by reduced NMDA/AMPA ratios (Blundell et al., 2010; Jedlicka
et al., 2013). Together, these results suggest that NLGN1 is
important in cognitive and repetitive behaviors characteristic of
autism although the relationship between LTP, NMDA receptor-
mediated synaptic transmission, and the observed behavioral
deficits remains unclear. Other studies have examined the role of
NLGN1 in a transgenic mouse model under a ubiquitous Thy1-
promoter to drive neuron-specific overexpression throughout
the brain (Hines et al., 2008; Dahlhaus et al., 2010). These
transgenic mice exhibited deficits in LTP and impairments in
memory acquisition on the Morris water maze test, which further
corroborates the importance of NLGN1 in synaptic plasticity
and cognitive processes (Hines et al., 2008). Recent studies have
shown that the conditional KO (CKO) of NLGN2 in the adult
medial prefrontal cortex results in the gradual loss of inhibitory
synapses (Liang et al., 2015). The authors deleted NLGN2 locally
via bilateral stereotactic injection of AAVs expressing GFP tagged
Cre-recombinanse. The mice exhibited impairments in anxiety-
like characteristics, fear memory, social interaction behaviors,
and alterations in inhibitory synaptic properties (Durieux et al.,
2015; Liang et al., 2015). The overexpression of NLGN2, which is
exclusively expressed at inhibitory synapses, resulted in enlarged
inhibitory synaptic contact size in the frontal cortex and an
overall reduction in the ratio between excitatory and inhibitory
synaptic activity (Hines et al., 2008). Furthermore, these animals
displayed hyperactivity, increased stereotypic jumping, elevated
anxiety-like behavior, and impaired social interactions but
normal sociability (Hines et al., 2008). Together, these results
confirm that NLGN2 plays an essential role at the inhibitory
synapse and suggest that it may also contribute to ASD-like
behaviors. Perhaps the best studied mouse model based on the
NLGN genes that is relevant to autism are the NLGN3 knock-in
(KI) mice harboring the R451C missense mutation (i.e., Arg451
is substituted with Cys451) because this mutation was shown to
be linked to autistic patients. The NLGN3 R451C KI mice had
a 90% decrease in NLGN3 protein levels in the forebrain based
on immunoblotting analysis (Tabuchi et al., 2007). In addition,
there was a slight decrease in the level of the NLGN1 isoform. The
NLGN3 R451C KI mice exhibited increases in inhibitory synaptic
transmission and deficits in social interactions but enhanced
spatial learning and memory. Thus, the R451C substitution of
NLGN3 acts as a gain-of-function mutation consistent with
patients with ASD (Jamain et al., 2008). Other studies have
demonstrated impaired tonic endocannabinoid signaling that is
responsible for the altered inhibitory transmission (Foldy et al.,
2013). Consistent with NLGN3 R451C KI, NLGN3KO mice
(Varoqueaux et al., 2006) display behavioral phenotypes relevant
to autism; including reduced ultrasonic vocalizations, a lack of
social novelty preference, and a decrease in total brain volume
(Radyushkin et al., 2009). Recent studies indicate that in both
NLGN3 R451C KI and KO mice, there appear to be changes in
synaptic mechanisms within the striatum that facilitate repetitive
behaviors associated with this disease (Rothwell et al., 2014).
NLGN4 KO mice were generated with a gene trap insertion
340 bp downstream of the first exon of NLGN4 (first coding
sequence) by BayGenomics. Since a small segment of the essential
esterase domain remains, NLGN4 is unable to bind to NRXNs
and therefore non-functional (Jamain et al., 2008). These KO
mice had selective reductions in reciprocal social interaction
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and less ultrasonic vocalizations in males upon the presentation
of anestrus female (Ey et al., 2012). Recent studies have also
reported pronounced perturbations of γ-oscillatory network
activity that is implicated in cognition (Hammer et al., 2015).
To examine if there is a functional redundancy among the
NLGN isoforms, Varoqueaux et al. (2006) generated NLGN1–3
triple KO (TKO) mice lacking their respective signal sequences
and extracellular esterase-like domain to abolish NLGN gene
expression completely. They chose to focus on NLGN1–3 due
to the high expression levels in the brains of newborn mice.
It is interesting to note that while NLGN3 is present at
both excitatory and inhibitory synapses, NLGN1 and NLGN2
appear to be exclusively expressed at excitatory and inhibitory
synapses respectively. These homozygous TKO mice had
apparent irregular breathing movements resulting in respiratory
failure and death shortly after birth (Varoqueaux et al., 2006).
Furthermore, impaired glutamatergic and GABAergic synaptic
transmission led to reduced excitatory drive and low spontaneous
synaptic activity (Varoqueaux et al., 2006). Therefore, these
results suggest that NLGN1–3 are critical for maintaining the
excitatory and inhibitory balance for proper synaptic activity.
In summary, the results from the mouse models based on
altered NLGN genes are consistent with the notion that changes
and mutations in the NLGN genes contribute to autistic
phenotypes likely through altered synaptic properties, including
abnormal excitatory/inhibitory balance, synaptic plasticity, and
endocannabinoid signaling.
SH3 and Multiple Ankyrin Repeat
Domains (Shanks)
The Shank family (Shank1–3) of genes code for post-synaptic
scaffolding proteins with multiple protein-protein interaction
domains (Naisbitt et al., 1999). These domains include a Src
homology 3 domain (SH3), ankyrin repeats domain (ANK),
post-synaptic density 95 PSD-95/disks large/zone occludens-
1 domain, a proline-rich region, a homer-binding region, a
cortactin-binding region, and a sterile alpha motif (Naisbitt
et al., 1999). The Shank proteins are localized to the post-
synaptic density and are important in coordinating the assembly
of signaling complexes at glutamatergic synapses (Bockers et al.,
2001; Durand et al., 2007). Mutations in Shank3 have been
strongly implicated in ASD compared to the other two Shank
family genes, and therefore, various lines of Shank3-mutant
mice have been generated to investigate the functional role of
each of the domains and its contribution to the neuropathology
of ASD. One of the first studies used the Cre/loxP system
to disrupt the exons coding for the ANK of Shank3 thereby
allowing regional-specific targeting of the gene (Bozdagi et al.,
2010). Specifically, the loxP sites were inserted to flank the
ANK and the floxed region was then excised by crossing it to
CMV-Cre transgenic mice. The Shank3-deficient mice displayed
reduced basal glutamatergic synaptic transmission and LTP along
the Schaffer collateral pathway and impaired reciprocal social
interactions including reduced social behavior reflected through
conspecific sniffing and vocalizations (Bozdagi et al., 2010).
Recent studies demonstrate that the homozygous deletion of
the ANK result in a significant reduction in NMDA/AMPA
ratio at the excitatory synapses onto striatal medium spiny
neurons and impairments in LTP (Jaramillo et al., 2015). The
haploinsufficiency of Shank3 or the loss of one functional copy
of the Shank3 gene results in chromosome 22q13 deletion
syndrome or Phelan-McDermid syndrome and autism (Phelan
et al., 2001; Uchino and Waga, 2013). Studies have genetically
targeted Shank3α, the longest Shank3 isoform that is responsible
for encoding the ANK without affecting Shank3β and Shank3γ
isoforms (Peca et al., 2011). Shank3α KO mice were found to
have modest ASD-like behavioral outcomes. Peca et al. (2011)
also created a second mouse line that targeted another isoform,
Shank3β, through the deletion of the exons coding for the
fragment containing the PSD-95/disks large/zonula occludens-
1 or PDZ domain. It is important to note that in this study,
the Shank3α-and β- isoforms were completely eliminated and
the Shank3γ- isoform was only significantly reduced (Peca et al.,
2011). These Shank3αβKO mice were found to have normal gross
anatomy but displayed anxiety-like behaviors and compulsive
repetitive grooming behavior that resulted in self-inflicted skin
lesions (Peca et al., 2011). However, individually, on tests of
social interaction, Shank3β KO mice were less sociable, while
Shank3α KO mice displayed mild impairments in social novelty
recognition (Peca et al., 2011). In a recent study, Speed et al.
(2015) knocked-in a single guanine nucleotide into exon 21 of
the Shank3 gene, which mimics an autism associated insertion
mutation and results in a frameshift causing a premature Shank3
protein. These mice displayed spatial learning deficits, impaired
motor coordination, and altered novelty and sensory processing
salient with the cardinal features of autism (Speed et al., 2015).
Therefore the results from the Shank3 mice are consistent
with the idea that deletions/mutations at the Shank3 gene
are contributing factors for ASD through regulating synaptic
function at excitatory synapses.
INTELLECTUAL DISABILITY
Intellectual disability is one of the most devastating neuro-
developmental disorders in children and young adults. ID
involves impairments in general mental abilities that affect
conceptual, social, and practical domains of everyday tasks.
Children with ID often have IQ scores approximately two
standard deviations below the population (Mandel and Chelly,
2004). This pervasive disorder manifests itself beginning at early
development and comorbid with other neurological conditions
including ASD, depression, and attention-deficit/hyperactivity
disorder. The prevalence of ID has been gradually increasing in
the last decade and said to affect 3% of the population (Chelly
and Mandel, 2001). Due to the severity and the social/economic
effect of the disease, numerous attempts have been made
to better understand the development and behavior in these
children. However, the complexity of other symptoms including
comorbid features renders it difficult to interpret the genetic
and environmental factors involved in the pathophysiology of
ID. ID is classified into two primary categories based on the
clinical presentation, syndromic and non-syndromic ID, which
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allows different candidate genes to be tested for genotype and
phenotype comparisons. Syndromic ID includes all patients
present with one or multiple clinical features or comorbidities,
whereas non-syndromic ID describes patients with ID as the
sole clinical feature. In this section, we will discuss selected
mouse models for both syndromic and non-syndromic ID and
illustrate how genetically altered mice are used to study the
etiology of ID.
p21-Activated Kinases
In the mammalian central nervous system, PAKs (p21-activated
kinases) are a family of serine/threonine protein kinases that
are activated by Rho-family small GTPases, such as RhoA,
Rac, and Cdc42 (Field and Manser, 2012). The PAK family is
divided into group I and II kinases based on the presence of
an autoinhibitory domain (AID). Since group II PAKs lack an
AID, binding by upstream Rho-family GTPases does not always
lead to consistent activation of the kinase (Manser et al., 1995;
Baskaran et al., 2012). Group I PAKs are involved in multiple
cellular processes particularly actin regulation, cell proliferation,
apoptosis, and gene expression and alterations in PAK1–3 are
associated with tumor formation, inflammation, and cognitive
dysfunction (Kumar et al., 2006; Zhao et al., 2006). Recent studies
have demonstrated that 25–35% of ID have genetic associations
with nonsense or missense mutations on the X chromosome,
some of which result from loss of function in the PAK3 gene
(Kelly and Chernoff, 2012). A number of mouse models have
thus been generated based on the PAK genes to investigate the
in vivo role of these genes and how their mutations contribute
to ID (Allen et al., 1998; Boda et al., 2004; Dubos et al., 2012).
Hayashi et al. (2004) generated a transgenic mouse model to
inhibit the catalytic activity of group 1 PAKs in the postnatal
forebrain. The dominant-negative PAK (dn-PAK) transgene,
which consisted of an α-CaMKII promoter, amino acids 74–
146 encoding the AID of PAK3, and SV40 intron/polyA, was
used to create the mouse model (Hayashi et al., 2004). The
dnPAK transgenic mice displayed decreased spine density and
increased proportion of large synapses in cortical pyramidal
neurons. Surprisingly, these mice showed enhanced AMPAR-
and NMDAR-mediated synaptic transmission and LTP (Hayashi
et al., 2004). Behaviorally, the dnPAK mice exhibited specific
impairments in the consolidation and retention of hippocampal-
dependent memory in a fear conditioning paradigm. These data
suggest that PAKs in general play a role in synaptic structure
and plasticity and cognitive processes. PAK1 and PAK3 single
KO mice were previously created by replacing a part of the
coding and adjacent upstream/downstream intronic sequence
by a pgk-neomycin resistant cassette to completely eliminate
the entire kinase domain of PAK1 and 3 respectively (Meng
et al., 2005; Asrar et al., 2009). PAK1 KO mice revealed normal
brain anatomy but selective deficits in LTP at hippocampal
CA1 synapses with changes in levels of actin binding protein,
cofilin (Asrar et al., 2009). PAK3 KO mice resulted in no
deficits in either cofilin activity or the actin cytoskeleton
with mild impairments in late-phase LTP and learned taste
aversion (Meng et al., 2005). In a recent study, Huang et al.
(2011) investigated the role of PAKs by analyzing double
knockout (DKO) mice lacking both PAK1 and PAK3 to eliminate
functional redundancy. The DKO mice were generated by
crossing previously characterized single PAK1 and PAK3 KO
mice (Meng et al., 2005; Asrar et al., 2009). The DKO mice
exhibited impaired postnatal brain growth, deficits in dendritic
arborization and spine morphology, with alterations in synaptic
transmission and plasticity (Huang et al., 2011). Furthermore, the
DKO mice displayed a host of behavioral deficits consistent with
ID-like symptoms including hyperactivity, increased anxiety, and
learning and memory deficits. The alterations in spines were
rescued by blocking cofilin activity suggesting cofilin-dependent
actin regulation may mediate the effect of PAK1 and PAK3.
Actin, the major cytoskeletal component in dendritic spines,
is known to regulate a host of synaptic properties particularly
post-synaptic receptor trafficking and spine morphology (Meng
et al., 2004). Since the genetic deletions of either PAK1 or
PAK3 in mice have only produced modest effects, PAK1 and
PAK3 appear to have at least some overlapping functions in
synaptic and cognitive regulation (Meng et al., 2005; Asrar
et al., 2009; Huang et al., 2011). Further, analyses of these single
and double KO mice will be needed to elucidate the in vivo
roles and detailed mechanisms of PAKs. In addition, mouse
models with specific PAK gene mutations relevant to ID will
be required to translate animal studies to human conditions.
Ultimately, these studies will help to reveal cellular and molecular
mechanisms involved in the pathogenesis of non-syndromic
x-linked ID.
Fragile X Syndrome
Fragile X syndrome is the most commonly inherited form of
ID and the most common cause of autism (O’Donnell and
Warren, 2002; Hayashi et al., 2007; Pietropaolo and Subashi,
2014). FXS is a genetic diagnosis affecting 1 in 1250 males and
2500 females (Crawford et al., 2001). More specifically, FXS is
a multi-organ disease with widespread effects leading to ID,
macroorchidism in males, and premature ovarian insufficiency
in females (Brennan et al., 2006; Ascano et al., 2012). FXS
patients exhibit an increased incidence of seizures, anxiety,
depression, and subtle motor impairments (Berry-Kravis et al.,
2007; Basuta et al., 2011; Chonchaiya et al., 2012). This
neurodevelopmental disorder is caused by the loss of the Fragile
X mental retardation protein (FMRP) encoded by the Fragile X
mental retardation 1 (FMR1) gene (Verkerk et al., 1991). Clinical
studies reveal that patients with FXS have increased expansion
and hypermethylation of trinucleotide (CGG) repeats within the
promoter of FMR1 (Fu et al., 1991; Kremer et al., 1991a,b). FMRP
is predominantly expressed within the cytoplasm of cells and
have been implicated in translational processes including RNA
interference and RNA subcellular localizations by facilitating
nucleo-cytoplasmic shuttling (Devys et al., 1993; Eberhard and
Grummt, 1996; Fridell et al., 1996). Human studies have
revealed that FXS patients have abnormal development and
morphological changes such as increased abundance of long,
thin, and immature dendritic spines (Hinton et al., 1991; Irwin
et al., 2001). The molecular mechanisms governing the spine
and behavioral anomalies observed in FXS are not clear but
analyses of FRMP mouse models based on the FMR1 gene
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have provided significant progress, which will be discussed
below.
Fragile X Mental Retardation Protein
In order to examine the effects of the FMRP, the Dutch-
Belgian Fragile-X Consortium engineered a mouse model in
which the wild-type murine FMR1 gene was knocked out
through introducing a neomycin cassette (Bakker et al., 1994; No
authors, 1994). The FMR1KO mice displayed similar phenotypic
characteristics seen in patients with FXS; including hyperactivity,
increased anxiety and depressive-like states, cognitive deficits,
and macroorchidism in male mice (Bregman et al., 1988; Bakker
et al., 1994; No authors, 1994; Kooy et al., 1996; Yuhas et al.,
2011). In a recent study, FMR1KO mice further showed reduced
social discrimination between a familiar and novel mouse
(Sorensen et al., 2015). However, FMR1KO mice lack FMRP
expression in the entire animal. Thus to specifically investigate
the spatial and temporal expression patterns of FMRP, the design
of more novel and versatile KO models were needed. Mientjes
et al. (2006) used the Cre/loxP system to disrupt the exons
coding for FMR1 to achieve Purkinje cell-specific expression. The
floxed region was then excised by crossing it to pcp-2/L7-Cre
expressing mice to generate conditional FMR1KO (CKO) mice
(Mientjes et al., 2006). These FMR1CKO mice revealed deficits
in classical cerebellar-mediated delay eye-blink conditioning
(Koekkoek et al., 2005). Amiri et al. (2014) used Nse-Cre
(neuron-specific enolase promoter-driven Cre transgene) mice
to drive loxP-specific deletion of FMR1 in subsets of neurons
in the mouse cortex and hippocampus at 4 weeks of age. The
FMR1CKO mice showed elongated spines and cell physiological
abnormalities at the parallel fiber synapses that form on these
spines (Amiri et al., 2014). Due to the similar sequence homology
and tissue distribution, FXR2P, a homolog of the FMRP, has
been suggested to compensate in part for the function of FMRP
which may explain the mild phenotypes observed in FMR1KO
mice (Kirkpatrick et al., 2001; Bontekoe et al., 2002; Mientjes
et al., 2006). FXR2KO mice were created through inserting
a neomycin resistant gene to study the function of FXR2P.
Similar to FMR1KO mice, FXR2KO mice exhibited hyperactivity
accompanied by mild disruptions on the rotarod test (Bontekoe
et al., 2002; Spencer et al., 2006). However, FXR2KO mice
exhibited less contextual conditioned fear, reduced prepulse
inhibition, and learning deficits on the Morris water maze
test, suggesting that FXR2 and FMR1 may play different roles
in FXS phenotypes (Bontekoe et al., 2002). To examine if
FXR2 and FMR1 have overlapping functions, other studies
have created the FMR1/FXR2 double KO (DKO) mice through
crossing individual FMR1KO and FXR2KO mice (Bontekoe
et al., 2002). These DKO mice demonstrate increased anxiety,
hyperactivity, reduced prepulse inhibition, and deficits in spatial
and associative learning and memory suggesting a functional
relationship between FXR2P and FMRP (Spencer et al., 2006).
Together, these different methods of targeting FMRP and FXR
proteins outline how these interactions can contribute to FXS
phenotypes. However, further analyses are needed to elucidate
the detailed cellular and molecular mechanisms involved in the
pathogenesis of FXS.
Williams- Beuren Syndrome
Williams- Beuren syndrome (WS) is a neurodevelopmental
disorder caused by the deletion of a 1.5-million-bp-segment on
chromosome 7 (7q11.23; Pober, 2010). This microdeletion is
caused by misalignment of chromosome 7, a region spanning
28 genes flanked by highly homologous clusters of genes during
meiosis that results in unequal homologous recombination and
consequently deletion (Pober, 2010). To date, WS is a rare
disorder that affects approximately 1 in 7500 births (Stromme
et al., 2002; Sanders et al., 2011). Patients with WS exhibit a
broad range of cognitive and systemic deficits. These include
congenital heart disease, an ID profile with an unusual pattern of
abilities (IQ of approximately 64 but are concrete in vocabulary
and verbal short-term memory), and weaknesses in visuospatial
construction and long-term memory (Mervis and John, 2010;
Mervis and Velleman, 2011). Genetic association studies have
implicated a variety of genes to contribute to the cognitive and
behavioral profile of WS. However, only a few of these targets
that reside in the commonly deleted hemizygous region have
exhibited consistent cognitive and behavioral deficits of WS when
translated to a mouse model. These include LIMK1 (Frangiskakis
et al., 1996), CLIP2 (Hoogenraad et al., 2002), GTF2I (Merla et al.,
2010), and GTF2IRD1 (Merla et al., 2010). Although, several
genetic models have been produced and characterized for these
genes, we will focus on LIMK1 KO mice that partially recapitulate
the behavioral and cognitive profile of WS.
Lim Domain Containing Kinase
Lim domain containing kinase 1 (LIMK1) is a serine/threonine
protein kinase and a potent regulator of actin dynamics
via phosphorylating and thus inactivating the actin-
depolymerization factor (ADF)/cofilin (Arber et al., 1998;
Yang et al., 1998; Sumi et al., 1999). In vitro studies have indicated
that the Rho family small GTPases, Rac1 and Cdc42, bind and
activate PAKs and ROCK protein kinases, which phosphorylate
and activate LIMK1 (DesMarais et al., 2005; Jia et al., 2009; Huang
et al., 2011). The activated LIMK1 can directly phosphorylate
and inactivate cofilin, which promotes actin polymerization
(DesMarais et al., 2005; Jia et al., 2009; Huang et al., 2011).
Human genetic studies reveal that WS patients with smallest
microdeletions containing the LIMK1 gene (Tassabehji et al.,
1996) show some key WS phenotypes (i.e., visuospatial deficit),
suggesting that LIMK1 may be a key factor in WS pathology. To
test this hypothesis, LIMK1KO mice were generated replacing a
part of the second LIM and PDZ domains with a pgk-neomycin
resistant cassette, to completely eliminate the kinase domain
(Meng et al., 2002). These mice had normal expression of other
proteins including LIMK2, PAKs, ROCK2, and cofilin, but
reduced cofilin phosphorylation and altered actin networks and
spine morphology. Behaviorally, the LIMK1KO mice displayed
deficits in locomotion, fear responses, and visuospatial cognition
(Meng et al., 2002). Recent studies have also identified that
LIMK1KO were particularly impaired in long-lasting LTP
(specifically late-phase LTP) and the formation of long-term
memory (Todorovski et al., 2015). In addition, LIMK1KO mice
were found to have a reduction in active (phosphorylated) CREB
and increasing CREB activity rescued the long-term memory
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deficits in these mice suggesting that impaired CREB signaling
may be responsible for late-LTP and long-term memory deficits.
Taken together, these studies indicate that the deletion of
LIMK1 is sufficient to cause synaptic dysfunction and impaired
long-term memory that may be relevant to WS. Therefore,
LIMK1 is likely a key factor in WS pathology. Furthermore, these
studies also suggest that LIMK1 regulates synaptic plasticity and
behavior via two distinct mechanisms; cofilin-mediated actin
reorganization and CREB-mediated gene expression. Ultimately,
these studies may provide insight into the neural circuitry and
molecular targets for treating and preventing WS.
SCHIZOPHRENIA
Schizophrenia is a chronic neuropsychiatric disorder
characterized by positive and negative symptoms, including
delusions, hallucinations, disorganized speech, catatonic
behavior, diminished emotional expression, and impaired
cognition (Abazyan and Pletnikov, 2014). Given the severity
and heterogeneity of these core symptoms, schizophrenia is
deemed to be one of the most debilitating diseases by the World
Health Organization, affecting approximately 1% of the entire
population. The onset of schizophrenia is in post-adolescence
(16–25 years), but the course of the illness and presentation
of core symptoms can persist into adulthood (40–60 years).
Although genetic and environmental factors contribute to
the etiology of schizophrenia, no specific biomarkers have
been identified for this multifactorial disorder. In a recent
study Ayalew et al. (2012) used a translational convergent
functional genomics approach to identify and prioritize genes
involved in schizophrenia. Through, gene-level integration of
genome-wide association data combined with gene expression
studies in humans and animal models, they identified top
candidate genes including: DISC1, NRG1, RELN, and many
others (Ayalew et al., 2012). Their findings shed light on novel
promising targets for future pharmacological treatments for
patients with schizophrenia. In this section, we will discuss two
well-characterized genetic mouse models of schizophrenia that
have recreated structural and behavioral dysfunctions associated
with the disease. In the end of this section, we will briefly discuss
alternate models that have been used to examine the effects of
dopamine and glutamate neurotransmission in schizophrenia.
Disrupted-in-Schizophrenia 1
Disrupted-in-Schizophrenia 1 (DISC1) is a scaffolding protein
with numerous binding partners that facilitate the formation of
protein complexes (Morris et al., 2003; Camargo et al., 2007).
In humans, DISC1 is 854 amino acids long consisting of a
N-terminal globular head domain and a long helical C-terminal
coiled tail domain (Chubb et al., 2008; Soares et al., 2011).
DISC1 is expressed systemically in the heart, liver, kidney, and
thymus, but highly enriched in the cerebral cortex, hippocampus,
hypothalamus, amygdala, cerebellum, and olfactory bulbs in
the brain (Ma et al., 2002; Austin et al., 2004; Brandon et al.,
2009). The DISC1 gene was first identified as a risk factor
for mental disorders including schizophrenia, schizoaffective
disorder, recurrent major depression, and adolescent conduct
and emotional disorder, in a Scottish pedigree that displayed
a translocation between chromosomes 1 and 11 (q42;q14.3; St
Clair et al., 1990). Since then, other studies have confirmed
that the translocation t(1;11) disrupts the DISC1 gene in several
populations, that are also susceptible to similar psychiatric
illnesses (Sachs et al., 2005; Chubb et al., 2008). The first
DISC1 mouse model was engineered based on a spontaneous
25-bp deletion in exon 6 of the DISC1 gene in a 129S6 strain
that abolished the production of the full-length DISC1 protein
(Koike et al., 2006). The DISC1-deficient mice exhibited cognitive
dysfunction specifically in spatial working memory (Koike et al.,
2006). In recent studies on the same DISC1-deficient mice, Kvajo
et al. (2011), found widespread and cumulative cytoarchitectural
alterations in the dentate gyrus during neonatal and adult
neurogenesis. In particular, they noticed errors in axonal
targeting and impaired dendritic growth that are accompanied
by changes in short-term plasticity at mossy fiber/CA3 synapses
(Kvajo et al., 2011). Furthermore, Juan et al. (2014) revealed subtle
working memory impairments were mediated by decreased
neuronal excitability and morphological alterations in layer
II/III pyramidal neurons in the medial prefrontal cortex in
the same DISC1-deficient mice. These studies suggest that
the DISC1 gene from the 129S6/SvEv strain is important
for neuronal connectivity, short-term synaptic dynamics and
working memory. Other models have been established based on
mutations in the mouse DISC1 gene via N-nitroso-N-ethylurea
(ENU) mutagenesis, which induces point mutations at a high
locus-specific rate (Coghill et al., 2002). Clapcote et al. (2007),
identified and analyzed two independently derived ENU-induced
missense mutations in the 955-bp exon 2 of mouse DISC1,
known as Q31L and L100P. They chose to focus on exon 2 due
to the fact that it is the longest, present in all known splice
isoforms, and encodes most of the head domain of the DISC1
protein (Millar et al., 2005; Clapcote et al., 2007). The Q31L
mice displayed depressive-like behavior or learned helplessness in
the forced swim test (FST), reduced sociability, and low sucrose
consumption indicative of anhedonia (Clapcote et al., 2007).
The L100P mice exhibited schizophrenic-like behavior with
profound deficits in prepulse inhibition and latent inhibition,
common methods to quantify information-processing deficits.
These L100P mice also had greater horizontal locomotion and
decreased working memory performance on the T-maze task
(Clapcote et al., 2007). The deficits observed in L100P mice
could be reversed by pharmacological or genetic inactivation
of glycogen synthase kinase 3 (GSK-3α and GSK-3β; Clapcote
et al., 2007). Similarly, the Q31L deficits in prepulse inhibition
and FST could be rescued following a GSK-3 blocker, TDZD-8,
suggesting a role for GSK-3 in mediating the effects of DISC1
(Lipina et al., 2012). Recent studies have shown that the Q31L
mice have fewer proliferating cells, whereas the L100P mice have
differences in the generation, placement, and maturation of newly
generated neurons in the adult hippocampus (Chandran et al.,
2014). Despite these differences, both models share structural
and functional brain abnormalities, particularly reductions in
overall brain volume due to tissue contraction in the neocortex,
thalamus, and cerebellum. Thus, both the Q31L and L100P
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mice exhibit impairments that are consistent with the positive,
negative, and cognitive symptoms of schizophrenia. In recent
studies, Lee et al. (2013) discovered altered interneuron density
and location in the L100P mice due to selective impairments
in calbindin- and parvalbumin-expressing interneurons in
the cortex and hippocampus, and consequently decreased
GAD67/PV co-localization in the neocortex, suggesting a role
of inhibitory transmission in schizophrenia. Lastly, there have
also been other transgenic models that result in the expression of
mutant DISC1 in a spatial-temporal manner. Hikida et al. (2007)
have exogenously expressed dominant-negative truncated DISC1
(DN-DISC1) under the regulation of an α-CaMKII promoter that
is restricted in the olfactory bulb, frontal cortex, hippocampus,
and basal ganglia. In this particular model, DN-DISC1 did not
affect the expression level of the endogenous DISC1 gene (Hikida
et al., 2007). Similar to patients with schizophrenia, the DN-
DISC1 mice displayed enlarged lateral ventricles contributing
to asymmetrical brain anatomy, interneuron deficits resulting
in cortical synchrony, and impairments in prepulse inhibition,
FST, and spontaneous activity. Therefore, analysis of the DISC1
mouse models has contributed significantly to and will continue
to provide new insights to our understanding of the in vivo
function of the DISC1 gene and how its alterations result in
schizophrenia.
Neuregulin-1
The family of neuregulins, also known as NDF, heregulin, GCF,
and ARIA (NRG1–4), are epidermal growth factors (EGFs) that
activate ErbB receptor tyrosine kinases, and play diverse roles
in normal developmental processes, plasticity, and oncogenesis
(Burden and Yarden, 1997; Harrison and Law, 2006; Britsch,
2007). Neuregulin-1 (NRG1), the best characterized amongst
the four neuregulins, was discovered in 1992 and shown
to have diverse functions in the heart, breast, and nervous
system (Holmes et al., 1992; Harrison and Law, 2006). In the
brain, NRG1 modulates neuronal migration, glial development
and differentiation, and synaptic transmission and plasticity
(Harrison and Law, 2006). In 2002, NRG1 was identified as
a candidate gene for schizophrenia in a genome-wide linkage
scan conducted by Stefansson et al. (2002). In this study, the
NRG1 gene was mapped to the chromosome 8p locus (8p11-
p21), a region linked to schizophrenia. Therefore, numerous
mouse models have been generated to examine the functional
consequences of targeting NRG1 and its receptor, ErbB. To
target the EGF-like domain, exon 6 of the NRG1 gene was
fused to β-galactosidase (NRG1-LacZ), which resulted in the
partial deletion of the EGF-like domain of all three isoforms
of NRG1 (Meyer and Birchmeier, 1995). Also, a second vector
was used that targeted exons 7–9, which encode parts of the
EGF domain (carboxy-terminus) of NGR1, was replaced by a
neomycin resistance gene (Meyer and Birchmeier, 1995). The
matings between heterozygous mice carrying either mutation
produced no homozygous mutant offspring, indicating that the
complete deletion of NRG1 and its receptor, ErbB, are lethal
during embryogenesis due to heart malformations and defects
in Schwann cells and cranial glia development (Meyer and
Birchmeier, 1995). Therefore, NRG1 and its ErbB receptor are
indispensable during development. In subsequent studies, the
NRG1 heterozygous mice were therefore used and found to
exhibit significant behavioral alterations such as hyperactivity in
the open field test, improved rotorod performance, and enhanced
spontaneous alternation ability in T or Y-maze tests (Gerlai et al.,
2000; Stefansson et al., 2002; O’Tuathaigh et al., 2007). Other
studies have shown that hyperactivity and increased locomotion
in NRG1 heterozygous mice can be reversed with clozapine
(an antipsychotic to treat schizophrenia) and environmental
enrichment (Karl et al., 2007; Duffy et al., 2008). Therefore,
the targeted deletion of NRG1 provides novel insights into
the role of NRG1 and supports that it may contribute to
schizophrenia. Several studies have also examined the effects of
increased NRG1 expression in transgenic mouse models. Kato
et al. (2010) constructed a transgenic vector that contained
the promoter of a house keeping gene, elongation factor 1α
(EF-1α) and GFP-tagged NRG1 cDNA that drives ubiquitous
expression in the whole brain. They confirmed through Western
blot and real-time quantitative reverse transcription that the
overexpression of NRG1 was 4.3-fold higher than wild-type
littermates (Kato et al., 2010). Behaviorally, the transgenic mice
had elevated locomotor activity, decreased context-dependent
fear conditioning, and impaired social interaction in an isolation-
induced resident-intruder test (Kato et al., 2010). Moreover, the
mice had an increased expression of GABAergic paravalbumin
and myelination markers in the frontal cortex, suggesting a
role for NRG1 in inhibitory transmission. Therefore, the mouse
models based on NRG1 presented in this section help to identify
the behavioral and mechanistic processes that may be relevant to
the pathophysiology of schizophrenia.
Although, we have discussed two well-characterized
genetic models used for studying the pathophysiological
mechanisms of schizophrenia, other studies exist that attribute
the pathological mechanisms of schizophrenia to dopamine
(DA) and glutamatergic neurotransmission dysfunction. The
DA hypothesis of schizophrenia proposes that hyperactive DA
transmission in the striatum contributes to positive symptoms of
schizophrenia while cognitive functions and negative symptoms
may result from hypoactive DA neurotransmission in the
prefrontal cortex (Carlsson and Lindqvist, 1963; Davis et al.,
1991; Howes and Kapur, 2009). Animal models have thus been
created to evaluate the roles of D2 receptors in neurotransmission
via inducible overexpression in the striatum alone (Kellendonk
et al., 2006). The D2 transgenic mice exhibited selective cognitive
impairments in working memory tasks that may be relevant to
schizophrenia (Kellendonk et al., 2006). In the second hypothesis,
glutamate receptors specifically NMDA receptor hypofunction
have been associated with the negative symptoms and cognitive
dysfunction similar to schizophrenia (Javitt and Zukin, 1991;
Coyle, 2006; Javitt, 2007). Studies have found that hypomorphic
NR1 mice with approximately 4% expression of NR1 (via
inserting a neomycin resistance gene into intron 20) exhibit
complex phenotypes including hyperactivity and decreased social
interactions (Mohn et al., 1999; Duncan et al., 2002). Therefore,
analysis of these models will be useful to determine the role and
underlying mechanisms of DA and glutamate transmission in
the pathogenic processes of schizophrenia.
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ALZHEIMER’S DISEASE
Alzheimer’s disease is a debilitating age-associated neuro-
degenerative disorder, affecting more than 35 million people
worldwide (Hall and Roberson, 2012). This neurocognitive
disorder results in a decline of intellectual function usually
beginning with impaired language usage or communication and
ultimately, interferes with one’s ability to function independently
(Janus and Borchelt, 2014). Therefore, as one of the most
devastating neurodegenerative disorders, potential biomarkers
have been developed via brain imaging such as MRI and PET
scans, genetic, and biochemical studies. AD has a well-defined
neuropathological profile including the presence of extracellular
amyloid plaques, accretion of intracellular neurofibrillary tangles
(NFTs), neuronal damage, and death in selected brain regions
(Arnold et al., 1991; Vigo-Pelfrey et al., 1993; Braak and Braak,
1994; Petersen et al., 1999; Naslund et al., 2000). Genetic linkage
and positional cloning strategies have identified various genes
associated with AD. These include: amyloid precursor protein,
presenilin 1 and 2, α-2 macroglobulin, low-density lipoprotein
receptor-related protein and others (Goate et al., 1991; Levy-
Lahad et al., 1995; Sherrington et al., 1995; Sperling et al., 2011).
In this section, we will discuss three genetic models targeting
amyloid-β-precursor protein, presenilin 1 and 2, and tau that are
involved in producing the AD phenotype.
Amyloid-β-Precursor Protein
Amyloid- β-precursor protein (APP) is a type I (single-pass)
transmembrane protein with a large amino-terminal extracellular
domain (O’Brien and Wong, 2011; Hall and Roberson, 2012).
Gene mutations in APP alter the production and deposition
of the amyloid-beta peptide (Aβ), which hasten the production
of extracellular amyloid plaques (Goate et al., 1991). The Aβ
peptides (36–43 amino acids long) are generated from APP by
β- and γ-secretase (Lewis et al., 2001). Alternative splicing of the
APP transcript generates eight isoforms, but only one (695 amino
acid form) is predominantly expressed in the CNS (Bayer et al.,
1999). The first genetic model to target APP used the PDGF-β
promoter to drive expression of APP717 cDNA gene encoding
a variant mutation where valine at residue 717 is substituted by
phenylalanine (V717F) that leads to overexpressing 40 copies of
the transgene (Games et al., 1995). This missense mutation in
APP is tightly linked to autosomal dominant forms of AD (Games
et al., 1995). These and other transgenic mice [i.e., the ones using
similar Thy1-APP (V717F)] displayed a ten-fold elevation of APP
protein and resulted in deficits in reference memory on the radial
arm maze and spatial memory on the Morris water maze test, and
an accumulation of amyloid in the brain between 6 and 7 months
(Games et al., 1995; Dodart et al., 1999; Moechars et al., 1999).
Therefore, overexpression of this mutant APP is sufficient for the
formation of amyloid plaques in mice. However, other anatomical
anomalies and their mechanisms were not investigated including
dystrophic neurites, the formation of NFTs, and reduced synaptic
density and function. Perhaps one of the best characterized
animal studies of AD is the Tg2576 transgenic mouse model,
which overexpresses a mutant APP containing Swedish FAD
(K670N/M67L) double mutations at the two β-secretase cleavage
sites responsible for Aβ production (Hsiao, 1998). Compared
to the previous model, the Tg2576 mice have moderate levels
of APP overexpression (5–6 fold of the endogenous level;
Hsiao, 1998). The mice had a slow accumulation of amyloid in
the neocortex and hippocampus around 12 months (Sturchler-
Pierrat et al., 1997; Kawarabayashi et al., 2001) and impaired
spatial reference and contextual memory (Comery et al., 2005).
Others have engineered transgenic mice harboring the Swedish
and London FAD mutations, revealing that these double mutants
have a sevenfold overexpression of APP with typical Aβ plaques
at the age of 6 months and 14–25% neuronal loss between
14 and 18 months (Calhoun et al., 1998). Behaviorally, these
mice showed a broad range of abnormalities that included
changes in limb and stereotypic movements, deficits in learning
and memory, and electrophysiological impairments in basal
synaptic transmission (Roder et al., 2003; Comery et al., 2005).
More recent studies have used a modified version of APP
where the Aβ peptide-coding domain of the mouse cDNA was
humanized (Borchelt et al., 1996). In these mice, APP was
expressed three-fold higher than the endogenous APP and were
found to develop amyloid plaques at old ages (24–26 months)
accompanied by various deficits in cognitive performance
(Borchelt et al., 1996; Savonenko et al., 2003). Recent studies have
shown that these mice with the overexpression of human APP
demonstrate reductions in synapse-associated proteins including
PSD95, AMPA and NMDA receptor subunits, and neuronal
maker, MAP2, indicating signs of neurodegeneration in the
hippocampus (Simon et al., 2009). Therefore, studies of mutant
APP transgenic mouse models have indicated that abnormal
expression of APP plays a critical role in AD pathology.
Presenilin
More than 150 familial mutations in presenilin 1 and presenilin
2 (PS1 and PS2) have been identified in AD (De Strooper,
2007). PSs encode the catalytic subunit of γ-secretase that
cleaves APP to form Aβ of varying lengths (De Strooper, 2007).
AD-associated PS mutations have been shown to increase the
two most common isoforms of Aβ, Aβ42 and Aβ40, both of
which are known to be responsible for the rate of amyloid
deposition (Borchelt et al., 1996; Scheuner et al., 1996). PSs
are also known to be involved in cell adhesion, calcium
homeostasis, transport, trafficking/localization, and apoptosis
(Hall and Roberson, 2012). To target PS1, several transgenic
mice expressing different forms of the human mutated PS1
genes were created, to explore whether mutations in PSs cause
cells to secrete a greater amount of amyloidogenic Aβ peptides
(Elder et al., 2010). The transgenic mice expressing mutant
human PS1 [lines Tg(M146L)1, Tg(M146L)76, Tg(L286V)198]
showed significant overproduction of Aβ42 and no cognitive
deficits in the Morris water maze test at 6 and 9 months
of age (Janus et al., 2000). Only mutant PS1 co-expression
with a mutant APP (Tg2576) showed early amyloid plaque
deposition, neuron loss in the cerebral cortex, and cognitive
dysfunction (Arendash et al., 2001; Lok et al., 2013). Taken
together, these studies suggest that the full phenotypic expression
of mutant PS1 alleles may require the co-expression of other
AD-associated genes. PS1 conditional knockout (CKO) mice
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were generated by crossing floxed PS1 mice with transgenic
mice expressing Cre recombinase under a αCaMKII promoter
so that PS1 was selectively inactivated in excitatory neurons
in the postnatal forebrain (Yu et al., 2001). The CKO mice
showed normal basal synaptic transmission and plasticity, but
exhibited mild deficits in spatial learning and memory. Other
studies have found that the conditional inactivation of PS1 in
APP transgenic mice prevented the accumulation of Aβ peptides,
the formation of amyloid plaques, and inflammatory responses
but failed to ameliorate the contextual memory and synaptic
deficits associated with APP transgenic mice (Saura et al., 2005).
Conditional PS1 and PS2 double knockout mice (PS CDKO)
revealed cortical shrinkage, hippocampal atrophy, and elevated
levels of tau hyperphosphorylation that was accompanied by
behavioral deficits in hippocampal-dependent learning and
memory (Feng et al., 2004; Saura et al., 2005). Therefore, these
results define essential roles of PSs in synaptic plasticity, learning
and memory, and neuronal survival in the adult cerebral cortex.
Tau
The genes discussed above focused on recapitulating the Aβ
pathology in the formation of extracellular plaques in AD.
However, AD also involves the development of intracellular
NFTs mainly comprised of hyperphosphorylated forms of the
microtubule-associated protein, tau (Lee et al., 2001). Studies
have revealed over 30 mutations in the microtubule-associated
protein, tau, in AD patients; ranging from missense, deletion, and
silent mutations in the coding region, and intronic mutations,
influencing the alternative splicing of tau or its protein level
(Clark et al., 1998; Hutton et al., 1998; Goedert, 2005). The first
tau KO mice were generated by replacing the signals for the
start of translation of tau protein with a pgk-neomycin resistant
cassette so that only short fragments incapable of binding to
microtubule were produced (Harada et al., 1994). In later studies,
these tau KO mice exhibited motor deficits and muscle weakness
(Ikegami et al., 2000). Dawson et al. (2001) have also generated
tau KO mice, on a BL/6/129sv mixed strain, and showed similar
locomotor deficits in balance beam tests, but in this latter model,
tau KO mice expressed significant cognitive deficits at 12 months.
Furthermore, the authors were able to show that primary
hippocampal neurons from the tau-deficient mice had delayed
maturation in their axonal and neuritic extensions (Dawson et al.,
2001). These results suggest that the genetic background of the
tau-deficient mice may result in discrepancies on the deleterious
effects of axonogenesis. Studies have shown that the ablation
of tau ameliorates AD-related synaptic, network, and behavioral
abnormalities in transgenic mice expressing human APP (Morris
et al., 2015). Transgenic mice expressing human tau containing
the P301L mutation (JNPL3) linked to frontotemporal dementia
and Parkinsonism have been produced under the mouse prion
promoter (Lewis et al., 2000). These mice were found to show
moderate early behavioral deficits in escape extension during
tail elevation and spontaneous back paw clenching (Lewis et al.,
2000). In addition, these mice developed a progressive motor
abnormality due to the loss of lower motor neurons (Lewis et al.,
2000). In a later study, when the JNPL3 mice were crossed with
the Tg2576 mice, there was an increase in the formation of
filamentous tau inclusions and plaques in the forebrain regions
compared to JNPL3 mice (Lewis et al., 2001). Behaviorally, these
double transgenic mice developed motor disturbances associated
with spinal cord and neuromuscular pathology. More recent
findings have proposed that post-translational modifications
such as acetylation and ubiquitination of endogenous tau, that
is not bound to microtubules and is free to interact with
diverse molecules in different neuronal compartments, mediates
Aβ-induced neuronal impairments (Morris et al., 2015). To study
the neuropathological correlates of AD, the interaction between
Aβ and tau and their effect on synaptic function was examined
in a triple transgenic mouse model (Oddo et al., 2003). Rather
than crossing three independent lines of mice, Oddo et al. (2003)
co-microinjected human tau (P301L) and Swedish FAD APP
mutation (both under the control of a Thy1.2 neuron-specific
regulatory element) into single-cell embryos from homozygous
PS1(M146V) KI mice. They successfully found five of the six
founder lines harbor all three mutations and in two lines the
transgenes appeared to cointegrate at the same genetic locus
(Oddo et al., 2003). The tight linkage coupled to the PS1 knockin
site allowed the mice to breed as a “single” transgenic line (Oddo
et al., 2003). The mice exhibited synaptic deficits (LTP) that were
manifested in an age-dependent manner, followed by plaques at
3 months of age and NFTs by 12 months in the cerebral cortex,
hippocampus, and amygdala (Oddo et al., 2003). These results
are consistent with the amyloid cascade hypothesis. Ultimately,
this triple Tg-AD mouse along with other AD models described
above will provide valuable tools to evaluate the interaction
and pathogenic mechanisms of various AD genes. Other models
such as those based on Apolipoprotein E (ApoE) gene are also
important to assess the involvement of glial cells in AD pathology,
but will not be discussed here.
PARKINSON’S DISEASE
Age-related neurodegenerative diseases also include PD, which
is becoming increasingly prevalent in our society. It is
estimated that 10 million people worldwide are affected by
PD (Hirtz et al., 2007). According to DSM-V, PD is a
progressive neurodegenerative disorder clinically characterized
by the cardinal symptoms of resting tremor, bradykinesia or the
slowness of movement, cogwheel rigidity, and postural instability
(Jankovic, 2008). Non-motor symptoms such as the presence of
Lewy bodies and neurites that consist of aggregated forms of
the 140 amino acid protein α-synuclein were also found in post-
mortem brain studies and therefore considered to be one of the
histological hallmarks of PD (Fearnley and Lees, 1991; Spillantini
et al., 1998; Braak et al., 2003). As the second most common
neurodegenerative disorder following AD, PD also attracts a great
deal of clinical and basic research. PD is characterized by the
loss of dopaminergic cells in the substantia nigra that project
to the striatum leading to nigrostriatal degeneration and motor
symptoms (Forno, 1996), but the mechanisms underlying this
cell loss remain unclear. Genetic models based on gene mutations
linked to the monogenic form of familial PD have been essential
tools for the mechanistic and treatment studies. In this section,
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we will discuss three different mouse PD models that have
been used in the attempt to evaluate possible neuroprotective
treatments and biomarkers for early diagnosis and disease-state
identification. It is important to note that none of the current
models have been able to precisely replicate all motor and
non-motor symptoms, as well as Lewy body formation and
nigrostriatal degeneration in an age-related progressive manner.
α-Synuclein
Alterations in α-synuclein (encoded by the SNCA gene)
cause a rare form of autosomal dominant PD. Mutations in
α-synuclein is known to be the most common risk factor
for idiopathic and familial PD (Pankratz et al., 2009; Satake
et al., 2009). PD-related point mutations (such as A30P and
A53T), rare triplications, and duplications in the SNCA gene
have been identified in human familial PD (Polymeropoulos
et al., 1997; Ahn et al., 2008; Gasser, 2009). Therefore, various
wild-type or mutant α -synuclein transgenic mice have been
developed to examine the consequences of overexpression
of the SNCA gene under different promoters. Specifically,
mice overexpressing human wild-type α-synuclein under
the platelet-derived growth factor-β (PDGF-β) promoter
(Line D) exhibited intraneuronal α-synuclein aggregates in
the neocortex, hippocampus, and olfactory bulb (Masliah
et al., 2000). Furthermore, these mice had lower striatal
levels of tyrosine hydroxylase (required for the synthesis of
dopamine) enzymatic activity associated with the degeneration
of nigrostriatal dopaminergic neurons (Masliah et al., 2000).
Behaviorally, the mice displayed rotarod and spatial memory
deficits. Thus, intraneuronal accumulation of α-synuclein
appears to be required for dopaminergic and behavioral deficits
to become detectable (Masliah et al., 2000; Masliah and Hansen,
2012). Another model was generated that overexpressed
mutant α-synuclein under the Thy1 promoter, which had a
more widespread expression of α-synuclein in neurons of
the thalamus, basal ganglia, substantia nigra, and brainstem
(Rockenstein et al., 2002). In this model, the human A53T
mutation in α-synuclein was introduced into the transgene
(van der Putten et al., 2000; Rockenstein et al., 2002). These
A53T transgenic mice showed late-onset pathological changes
that include axonal degeneration in long white matter tracts
of the spinal cord, the breakdown of myelin sheaths, and
the degeneration of neuromuscular junctions with a loss of
integrity of the presynaptic neurofilament network (van der
Putten et al., 2000; Rieker et al., 2011). In an another study,
Plaas et al. (2008), generated a mouse model with a subtle
point mutation in α-synuclein that replaced alanine with
proline at position 30 (A30P). The A30P mice exhibited an
age-dependent decline in motor ability on the beam walk
test and in mean stride length from all paws (Plaas et al.,
2008). Furthermore, the SNCA A30P mice had deficiencies
in vmat2, a vesicular transporter that regulates dopamine
availability, which indicates that the motor defects may be
due to a decreased content of dopamine in the striatum.
Double transgenic mice harboring the A30P/A53T mutations
displayed progressive decline with age in locomotor activity and
stereological counts of tyrosine hydroxylase-positive neurons
(Thiruchelvam et al., 2004). In addition to overexpression
studies, others have also engineered α-synuclein KO mice. The
KO mice were generated by using a floxed neomycin cassette
to disrupt the SNCA gene and subsequently crossed with
C57BL/6NTacGt(ROSA)26Sortm16(cre)Arte mice (Chandra
et al., 2004). These KO mice had normal ultrasynaptic structure
and survival rates but displayed decreased striatal dopamine
levels (20%), elevated lactate concentrations, and reduced
rearing (Chandra et al., 2004; Drolet et al., 2004). These findings
suggest that α-synuclein may play a role in the maintenance
of presynaptic vesicular function. Chandra et al. (2005) show
that transgenic expression of α-synuclein ameliorates the
lethality and rapidly progressive neurodegeneration caused by
the deletion of cysteine-string protein-α (CSPα), a synaptic
vesicle protein essential for neuronal survival, in mice. The
expression of transgenic α-synuclein improved SNARE complex
assembly, which suggests that α-synuclein acts in conjunction
with CSPα to play an important role in protecting presynaptic
terminals against neurodegeneration. Triple αβγ-synuclein
KO mice that lack all murine synucleins (generated through
breeding previously characterized αβ-synuclein KO mice with
γ-synuclein KO mice) present age-dependent alterations in
synaptic structure and transmission, neuronal dysfunction,
diminished survival, and late-onset phenotypes including retinal
dysfunction (Burre et al., 2010; Greten-Harrison et al., 2010).
Therefore, mouse models of altered α-synuclein expression have
increased our understanding of the role of α-synuclein in PD
related processes.
Leucine-Rick Repeat Kinase 2
Missense mutations in the leucine-rich repeat kinase (LRRK2)
gene have been identified as causes of autosomal dominant
PD with characteristics similar to the sporadic disease forms
(Singleton, 2005; Cookson and van der Brug, 2008). LRKK2
is a 2527- amino acid protein consisting of several functional
domains, including a leucine-rich repeat domain, a Ras-like
small GTPases domain, and a kinase domain with sequence
homology to MAP kinase (Tong and Shen, 2009). KO models
have been generated for LRRK2 by flanking the first loxP site
at intron 1 followed by, a neomycin expression cassette, and
the second loxP at intron 2 of the LRRK2 gene (Parisiadou
et al., 2009). These KO mice, resulting from crossing the floxed
mice with EIIa-Cre-transgenic mice, were viable to adulthood
and did not show any major abnormalities, suggesting that
LRRK2 may not play a major role in the development and
survival of dopaminergic neurons (Andres-Mateos et al., 2009;
Parisiadou et al., 2009; Li et al., 2011). Recent studies have
shown that the LRRK2 KO mice show increased protein kinase
A- mediated phosphorylation of cofilin and glutamate receptor
1 (GluA1) and impaired synaptic transmission in the striatum
(Parisiadou et al., 2014). Associations of LRRK2 have been found
with microtubule dynamics, in particular the increased levels
of soluble β-tubulin in LRRK2 KO mice (Gillardon, 2009). To
date, there is no genetic support for the causal involvement
of LRRK1, the closest paralog of LRRK2, in PD. Although,
LRRK1 and LRRK2 share a high sequence homology in the brain,
they function independently through interactions with different
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cellular proteins (Reyniers et al., 2014). LRRK1/LRRK2 double
KO mice are available through Jackson Laboratories, but have not
been characterized. Initial linkage studies have identified various
LRRK2 missense mutations including G2019S and R1441G in
patients with PD (Chen et al., 2012; Herzig et al., 2012).
LRRK2 overexpression mouse models were created that bear the
inducible G2019S mutation at the conserved Mg2+ binding motif
within the kinase domain and resulted in consistently enhanced
LRRK2 acitivty (Gilks et al., 2005; Nichols et al., 2005; West
et al., 2005; Lin et al., 2009). This familial PD-related mutation
caused impairments in dopaminergic neurotransmission that
was linked to modified localization and phosphorylation of the
microtubule-binding protein tau and consequences in motor
function (Li et al., 2010; Melrose et al., 2010; Winner et al.,
2011). Mice harboring the R1441G mutation demonstrate a
strong behavioral phenotype and altered dopamine release
recapitulating the cardinal features of PD (Li et al., 2009). In
particular these mice showed reduced rearing by 12 months
that could be rescued by L-DOPA suggesting that the behaviors
are dependent on dopamine. In a more recent study, R1441G
KI mice showed perturbed dopamine homeostasis resulting in
presynaptic dysfunction and locomotor deficits (Liu et al., 2014).
Thus, LRRK2 mouse models have been shown to be a useful
tool to understand the role of dopaminergic dysfunction in
PD.
Parkin, Phosphatase and Tensin
Homolog (PTEN)-Induced Putative
Kinase-1 and DJ-1
Other studies indicate that autosomal recessive forms of familial
PD are due to gene mutations in parkin, PTEN-induced putative
kinase 1 (PINK1), and DJ-1 (Bonifati et al., 2003b). Parkin is an
ubiquitin E3 ligase that is important in adenosine triphosphate-
dependent protein degradation (Zhang et al., 2010). Parkin KO
mice, with exon 2 replaced with the neomycin-resistant gene,
show mild, progressive motor deficits but normal emotionality,
learning and memory (Perez and Palmiter, 2005; Harvey et al.,
2008). Other parkin KO models have showed that the deletion of
exon 3 resulted in reduced synaptic excitability in the nigrostriatal
pathway and severe motor impairments in the beam traversal and
rotarod tasks (Goldberg et al., 2003). Recent studies indicated
that mice with the parkin gene deletion on exon 3 have normal
olfaction, anxiety, and depressive-like behaviors, but short-term
spatial memory deficits (Rial et al., 2014). However, in all of these
KO models, the progressive loss of nigrostriatal dopaminergic
neurons or enhanced vulnerability to dopaminergic neurotoxins
were not observed (Rial et al., 2014). This suggests that these
KO models may be only useful in studying the early-onset stages
of PD. Other studies have created transgenic mice expressing a
truncated human mutant parkin (Q311 X) driven by a Slc6a3
dopamine transporter promoter (Lu et al., 2009). The parkin-
Q311X mice developed age-dependent dopaminergic neuron
degeneration in the substantia nigra and showed late-onset
and progressive motor deficits (Lu et al., 2009). This study
provides evidence for dominant-negative modulatory effects of
a parkin mutant on dopaminergic neuron degeneration and
hypokinetic motor deficits in PD. Parkin selectively binds to
PINK1 and upregulates PINK1 levels, which affects the stability,
solubility, and formation of Lewy bodies (Um et al., 2009).
PINK1 is a mitochondrial serine/threonine kinase, implicated in
apoptosis, mitochondrial dysfunction, and impaired dopamine
release (Gandhi et al., 2006). One of the first studies to generate
conditional PINK1-silenced transgenic mice used the Cre/loxP
inducible system to regulate the expression of PINK1 shRNA
by crossing it to CMV-Cre transgenic mice (Zhou et al.,
2007). However, these mice showed no striatal dopaminergic
neurodegeneration or changes in nigral dopaminergic neuron
numbers, and no impairments in motor activity (Zhou et al.,
2007) suggesting that the silencing of PINK1 by conditional RNA
interference is insufficient to cause dopaminergic neuron death
salient with PD. In another study, PINK1 KO mice were created
by deleting the kinase domain through introducing a nonsense
mutation (Kitada et al., 2007). These KO mice had a normal
number of nigral dopaminergic neurons but impairments in
corticostriatal LTP and LTD that could be rescued with dopamine
receptor agonists (Kitada et al., 2007). Thus, the full rescue of the
synaptic deficits indicates that post-synaptic D1 and D2 receptor
function is intact and suggest specific presynaptic dopaminergic
defects and loss of dopaminergic terminals (Kessler et al.,
2005). The precise function of DJ-1 is unknown, however, it
has been found to be important in protecting mitochondria
against oxidative stress, cellular transformation, transcriptional
regulation, and androgen-receptor signaling (Lev et al., 2007).
The DJ-1 gene encodes a ubiquitous, highly conserved protein
predominantly expressed in neurons and glia cells (Canet-Aviles
et al., 2004). Human studies have shown that deletion of the
first five exons of the DJ-1 promoter result in progressive
neurodegeneration (Bonifati et al., 2003a,b). Thus DJ-1 null mice
were generated, lacking the first five exons and part of the
promoter region of DJ-1, to mimic the human deletion (Chen
et al., 2005). These mice showed age-dependent progression
of motor deficits and significantly increased levels of striatal
dopamine (Chen et al., 2005). Other studies have examined DJ-1
KO mice through disrupting exon 2, the first coding exon of DJ-
1 (Kim et al., 2005). These mice had no changes in nigrostriatal
dopamine levels but decreased motor functions (Kim et al.,
2005). Together these studies suggest that the loss of parkin,
PINK1, or DJ-1 induces motor impairments consistent with
the PD phenotype, though their effect on striatal dopaminergic
degeneration is inconclusive. Therefore, recent studies have
examined the synergistic effects of inactivating all three recessive
PD genes that are believed to be essential for the survival of
nigral neurons. These triple parkin, PINK1, and DJ-1 KO mice
(TKO) were generated by first crossing parkin KO with DJ-1 KO
mice, which were then interbred to obtain double parkin/DJ-1
KO mice (Kitada et al., 2009). PINK heterozygous mice were
then crossed with parkin KO/DJ-1 heterozygous mice to obtain
TKOs. The TKO mice were viable and fertile with no overt brain
anatomical abnormalities (Kitada et al., 2009). Surprisingly, these
TKO mice showed normal morphology and did not result in a
loss of dopaminergic neurons in the substantia nigra and locus
coeruleus at ages ranging from 3, 16, 24 months (Kitada et al.,
2009). This suggests that all three recessive genes are not required
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for the survival of dopaminergic neurons but may be protective
against age-dependent disruptions in PD.
CONCLUSION
In this review, we have briefly discussed selected mouse models
of a number of brain disorders that are generated using
genetic manipulation techniques, including transgenic mice and
knockout/knock-in plus conditional Cre/loxP and inducible
systems. The brain diseases that we have focused on include
childhood developmental disorders such as autism, ID, FXS,
and Williams-Beuren syndrome, neuropsychiatric disorders such
as schizophrenia, and neurodegenerative disorders such as AD
and PD. It is clear that availability of these mouse models has
enabled systematic investigations of the in vivo function of many
disease-related genes at various levels from gene to behavior,
and thus contributed significantly to our understanding of the
neurobiological basis of the diseases. It is expected that further
analysis of these existing mice, plus additional models with more
precise spatial and temporal specificity, will continue to reveal
new findings that will enhance our understanding and treatment
of various brain diseases.
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